1. Hill DA, Spergel JM (2018): The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol 120: 131-137.
2.
Grabenhenrich L, Trendelenburg V, Bellach J, et al. (2020): Frequency of food allergy in school-aged children in eight European countries-The EuroPrevall-iFAAM birth cohort. Allergy 75: 2294-2308.
3.
Stern J, Pier J, Litonjua AA (2020): Asthma epidemiology and risk factors. Semin Immunopathol 42: 5-15.
4.
Khreis H, Cirach M, Mueller N, et al. (2019): Outdoor air pollution and the burden of childhood asthma across Europe. Eur Respir J 54: 1802194.
5.
Haktanir Abul M, Phipatanakul W (2019): Severe asthma in children: Evaluation and management. Allergol Int 68: 150-157.
6.
Sigurdardottir ST, Jonasson K, Clausen M, et al. (2021): Prevalence and early-life risk factors of school-age allergic multimorbidity: The EuroPrevall-iFAAM birth cohort. Allergy 76: 2855-2865.
7.
Bjerg A, Hedman L, Perzanowski MS, et al. (2007): Family history of asthma and atopy: In-depth analyses of the impact on asthma and wheeze in 7- to 8-year-old children. Pediatrics 120: 741-748.
8.
Özdemir Ö (2023): Safety of biologicals in severe asthma patients having COVID-19. Pediatr Pulmonol 58: 2140-2141.
9.
Blazowski L, Majak P, Kurzawa R, et al. (2021): A severity grading system of food-induced acute allergic reactions to avoid the delay of epinephrine administration. Ann Allergy Asthma Immunol 127: 462-470.e2.
10.
Flokstra-de Blok BMJ, DunnGalvin A, Vlieg-Boerstra BJ, et al. (2009): Development and validation of a self-administered Food Allergy Quality of Life Questionnaire for children. Clin Exp Allergy 39: 127-137.
11.
Chase NM, Littlejohn M, Holweg CTJ, et al. (2024): Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma. Respir Med 223: 107537.
12.
Stelmach I, Majak P, Jerzyńska J, et al. (2015): Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland. Arch Med Sci 11: 901-904.
13.
Špičák V (2018): Doporučené postupy pro provádění expozičních testů s potravinami [Internet]. Available from: http://www.medvik.cz/link/MED00204395
14.
Yu L, Zhang H, Pan J, Ye L (2021): Pediatric usage of omalizumab: A promising one. World Allergy Organ J 14: 100614.
15.
Humbert M, Busse W, Hanania NA, et al. (2014): Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2: 525-536.e1.
16.
Gyawali B, Georas SN, Khurana S (2025): Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev 34: 240088.
17.
Casale TB, Luskin AT, Busse W, et al. (2019): Omalizumab effectiveness by biomarker status in patients with asthma: Evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract 7: 156-164.e1.
18.
Bernstein JS, Wechsler ME (2023): Eosinophilic respiratory disorders and the impact of biologics. Curr Opin Pulm Med 29: 202-208.
19.
Witonsky J, Elhawary JR, Millette LA, et al. (2023): Similar response to omalizumab in children with allergic asthma from different racial backgrounds. J Allergy Clin Immunol Pract 11: 2911-2913.
20.
Brannick S, McDonald M, Greally P, et al. (2022): Omalizumab for the treatment of severe allergic asthma in children: A tale of two. Clin Case Rep 10: e6255.
21.
Deschildre A, Marguet C, Salleron J, et al. (2013): Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 42: 1224-1233.
22.
Henriksen DP, Bodtger U, Sidenius K, et al. (2020): Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol 2020; 16: 49.
23.
Jesenak M, Zelieskova M, Repko M, Banovcin P (2020): Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome. Cent Eur J Immunol 45: 361-363.
24.
Sztafińska A, Gwardys M, Podlecka D, et al. (2021): Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland. Postepy Dermatol Alergol 38: 427-432.
25.
Ghouri H, Habib A, Nazir Z, et al. (2024): Omalizumab for the reduction of allergic reactions to foods: a narrative review. Front Allergy 5: 1409342.
26.
Casale TB, Fiocchi A, Greenhawt M (2024): A practical guide for implementing omalizumab therapy for food allergy. J Allergy Clin Immunol 153: 1510-1517.
27.
Kupryś-Lipińska I, Kuna P (2014): Loss of asthma control after cessation of omalizumab treatment: real life data. Postepy Dermatol Alergol 31: 1-5.
28.
Wood RA, Togias A, Sicherer SH, et al. (2024): Omalizumab for the treatment of multiple food allergies. N Engl J Med 390: 889-899.
29.
Mortz CG, Parke L, Rasmussen HM, et al. (2024): A randomized, double-blind placebo-controlled study on the efficacy of omalizumab on food allergy threshold in children with severe food allergy. Allergy 79: 964-976.
30.
Arasi S, Cafarotti A, Galletta F, et al. (2025): Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study. Allergy 80: 1074-1085.
31.
Anagnostou A, Bird JA, Chinthrajah S, et al. (2025): The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 155: 62-69.e1.
